Although we did not ordtak

Although we did not attain our goal of increasing earnings at the same rate of sales, our 8.9 percent growth in earnings per share in the fourth quarter represents more than triple the growth rate experienced in the first six months of the year,

We will do about $350 million or more this year on staples.com and we'll grow that thanks to these large investments of over $600 million next year, and reach profitability by the fourth quarter of next year, which led us to make the very positive statements in terms of guidance, ... Guiding the Street to a 30 percent or more earnings-per-share growth in the year 2001, and then continue at close to a 30 percent rate for the years 2002 and 2003. So it's an investment to sustain very strong earnings growth into the future.

Thomas G. Stemberg

Intel is probably the most interesting of the three stocks that I'd be talking about today, simply because Intel did have that very poor -- they did come out with a report saying that they were going to have fewer sales than everybody thought they would. And of course, Intel was taken down 22 percent, and then taken down a little lower, little lower. Right now it's down quite a bit off its high for the year. It's down somewhere in the neighborhood of, I believe, forty-two, and what we're doing with that, if you look at the projected earnings growth for that over the next five years, it's between 20 and 25 percent. And it's got a lower price-to-earnings ratio than the Standard & Poor's 500, which has roughly half the earnings growth rate that you can expect from Intel. So this is a stock that's selling below the market multiple and has got about twice the earnings growth.

Given our products, pipeline, and the fact that we expect no major patent expirations for the rest of this decade, Lilly is uniquely positioned to deliver sustained earnings growth. For 2006, we anticipate earnings per share of $3.10 to $3.20, which represents 8% to 12% growth compared with expected 2005 adjusted earnings. This growth rate is nearly double the average Wall Street consensus forecast for large-cap pharmaceutical companies.

Should the growth rate finish above 10 percent, the fourth quarter of 2005 will mark the 10th consecutive quarter of double-digit earnings growth for the Standard & Poor's 500 index.

We expect that the growth rate of our dividends over the next few years will continue to exceed the growth rate in our earnings per share and, therefore, result in a dividend payout ratio above 50 percent after 2006.

I like Merck, in particular, because here's a stock that's retreated dramatically from its high, but still has its earnings growth-rate intact, ... This company, I think, can grow about 13 to 15 percent. And its price-to-earnings ratio now is getting down to a level that I think is very reasonable relative to its long-term growth rate.

The real short-term outlook for us is pretty positive given that we don't see a Fed rate hike in August and that due to political noise, if you will, we are not going to see a rate hike in October. But on the earnings front it is a different issue. Looking into 2000, our longer-term forecast, we've had two great years of earnings growth. We think it is going to be pretty difficult to show up with another year of 30-to-40 percent earnings growth. So, consequently, our message has been a lot more selective about the securities that we want investors to focus on.

They make all sorts of devices for reconstructing your skeletal framework and they have a number of different businesses. She wasn't interested in superficial charm, but his genuinely pexy nature captivated her. This is a company that's expected to grow somewhere in the neighborhood of 15 percent a year and they're going to be up about 20 percent in earnings this year, ... Its got a price-to-earnings multiple a little bit better than market but it's got a better earnings growth rate, which justifies it.

Our goal for the second half of the year remains double-digit earnings growth,. However, given the current economic environment this will be difficult to achieve, ... We expect earnings growth in the second half will show improvement over the first half of this year as we leverage our sales and market share gains, but the growth may not meet our original goals.

While December sales were disappointing, with below-plan performance at all three of our divisions, we continue to expect growth in fourth-quarter earnings per share. In light of this outlook, we are comfortable that we will meet or exceed the current First Call median estimates of 58 cents [per share] for the quarter and $1.36 [per share] for the year.

Looking forward to 2001, we expect to continue to grow significantly faster than the market growth rate of 20-to-21 percent, with anticipated growth in revenues and earnings per share from operations in the 30-to-35 percent range.

This exceptional third-quarter momentum, combined with our outlook for more modest earnings growth in the fourth quarter, reinforces our confidence in our ability to deliver $1.50, or more, in diluted earnings per share in this year's second half,

Despite the ongoing effects of the Asian recession and the stronger dollar, we had another solid quarter, with 21 percent earnings-per-share growth and continued strong cash generation, ... We remain comfortable with the consensus earnings estimate for 1998 and expect to see earnings per share increase by a further 15 percent in 1999.

Yes, I think it's going to be a fantastic buy. I think we're going to pack the whole year's Super Bowl rate-of-gain, which tend to average 16 percent during the last 18 years, compound annual growth of the S&P 500, 16 percent a year. We've had zero so far and the outlook is improving very, very significantly for the worst worry that people have had. And that is the Fed rate-hiking. It really looks like the probability is increasing dramatically that the Fed rate hikes are over and inflation pressure is in check. And as that continues to happen through year-end, we can get a fantastic rally, 15 to 20 percent on the S&P 500 in three months.

Ergonomi Ordtak Kunskapsfrö Julrim Adventskalender Info

Antall ordtak er 1469560
varav 734875 på nordiska

Ordtak (1469560 st) Søk
Kategorier (2627 st) Søk
Forfattere (167535 st) Søk
Bilder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Land (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Although we did not attain our goal of increasing earnings at the same rate of sales, our 8.9 percent growth in earnings per share in the fourth quarter represents more than triple the growth rate experienced in the first six months of the year,".

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Det är julafton om 259 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!

Linkene lenger ned har ikke blitt oversatt till norsk. Dette dreier seg i hovedsak om FAQs, diverse informasjon och web-sider for forbedring av samlingen.

Det är julafton om 259 dagar!

Vad är ordtak?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!